Skip to Content
Merck
All Photos(1)

Documents

N6037

Sigma-Aldrich

Neridronate

≥97% (NMR), solid, bone resorption inhibitor

Synonym(s):

6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H17NO7P2
CAS Number:
79778-41-9
Molecular Weight:
277.15
MDL number:
MFCD00866995
UNSPSC Code:
51111800
PubChem Substance ID:
24724553
NACRES:
NA.77

product name

Neridronate, ≥97% (NMR), solid

description

may contain <1% (w/w) inorganic salts

Quality Level

100

Assay

≥97% (NMR)

form

solid

color

white

solubility

H2O: >5 mg/mL

storage temp.

2-8°C

SMILES string

NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)

InChI key

PUUSSSIBPPTKTP-UHFFFAOYSA-N

Biochem/physiol Actions

Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Massimo Varenna et al.
Rheumatology (Oxford, England), 52(3), 534-542 (2012-12-04)
Complex regional pain syndrome type I (CRPS-I) is a severely disabling pain syndrome for which no definite treatment has been established. The aim of this multi-centre, randomized, double-blind placebo-controlled trial was to test the efficacy of the amino-bisphosphonate neridronate in
Daniela Merlotti et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 26(3), 512-518 (2010-09-04)
Aminobisphosphonates actually represent the most common treatment for Paget disease of bone (PDB). In a previous study we demonstrated that either zoledronic acid (4 mg) or neridronate (200 mg) given as a single intravenous infusion showed a similar short-term efficacy
Daniela Merlotti et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 22(10), 1510-1517 (2007-07-04)
This randomized study compared different intravenous bisphosphonates in PDB. Zoledronate was superior with respect to pamidronate in achieving biochemical remission, with therapeutic response maintained in most patients at 15 mo. Single neridronate and zoledronate infusion showed a similar efficacy in
Imène Chebbi et al.
International journal of pharmaceutics, 383(1-2), 116-122 (2009-09-15)
Bisphosphonates have been used for decades in the standard therapy of bone-related diseases, including bone metastasis of various malignancies, and they might as well be toxic on early cancer cells themselves. In order to allow a better delivery of neridronate
Gian Luca Forni et al.
British journal of haematology, 158(2), 274-282 (2012-05-11)
Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service